Phase II trial of menogarol in the treatment of advanced adenocarcinoma of the pancreas Journal Article

  


Authors: Sternberg, C. N.; Magill, G. B.; Cheng, E. W.; Hollander, P.
Article Title: Phase II trial of menogarol in the treatment of advanced adenocarcinoma of the pancreas
Abstract: Fifteen patients with advanced adenocarcinoma of the pancreas were treated with menogarol 150-225 mg/m2 i.v. every 3 weeks. All patients had bidimensionally measurable disease. This regimen and dosage schedule are well tolerated, with minimal toxicity that included myelosuppression; median white blood cell (WBC) count nadir 2,700 cells/mm3 (range 1,400-7,100 cells/mm3) and median platelet nadir of 162,000 cells/mm3 (range 53,000-390,000 cells/mm3). Anorexia occurred in one patient, nausea or vomiting in six, phlebitis in one, and alopecia in six patients. No patients responded. At this dosage and schedule, there is no role for menogarol in the treatment of advanced pancreatic adenocarcinoma.
Keywords: clinical article; phase 2 clinical trial; age; pancreas carcinoma; intravenous drug administration; menogaril; human; male; female
Journal Title: American Journal of Clinical Oncology
Volume: 11
Issue: 2
ISSN: 0277-3732
Publisher: Lippincott Williams & Wilkins  
Date Published: 1988-04-01
Start Page: 174
End Page: 176
Language: English
DOI: 10.1097/00000421-198804000-00017
PUBMED: 2965856
PROVIDER: scopus
DOI/URL:

https://www.scopus.com/inward/record.uri?eid=2-s2.0-0023940361&doi=10.1097%2f00000421-198804000-00017&partnerID=40&md5=c72635578064292ab8157f652a21f2ac
Notes: Article -- Export Date: 6 August 2020 -- Source: Scopus
Altmetric
What is Altmetric?
Citation Impact
What is Dimensions Citation Badge?
BMJ Impact Analytics
MSK Authors
  1. Gordon B. Magill
    30 Magill
  2. Cora N. Sternberg
    36 Sternberg
  3. Edgar Cheng
    16 Cheng
Related MSK Work